Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial.

von Groote-Bidlingmaier F, Patientia R, Sanchez E, Balanag V Jr, Ticona E, Segura P, Cadena E, Yu C, Cirule A, Lizarbe V, Davidaviciene E, Domente L, Variava E, Caoili J, Danilovits M, Bielskiene V, Staples S, Hittel N, Petersen C, Wells C, Hafkin J, Geiter LJ, Gupta R.

Lancet Respir Med. 2019 Jan 7. pii: S2213-2600(18)30426-0. doi: 10.1016/S2213-2600(18)30426-0. [Epub ahead of print]

PMID:
30630778
2.

Compassionate use of delamanid in combination with bedaquiline for the treatment of multidrug-resistant tuberculosis.

Hafkin J, Hittel N, Martin A, Gupta R.

Eur Respir J. 2019 Jan 10;53(1). pii: 1801154. doi: 10.1183/13993003.01154-2018. Print 2019 Jan. No abstract available.

PMID:
30361253
3.

Final treatment outcomes of multidrug- and extensively drug-resistant tuberculosis patients in Latvia receiving delamanid-containing regimens.

Kuksa L, Barkane L, Hittel N, Gupta R.

Eur Respir J. 2017 Nov 9;50(5). pii: 1701105. doi: 10.1183/13993003.01105-2017. Print 2017 Nov. No abstract available.

PMID:
29122917
4.

Early outcomes in MDR-TB and XDR-TB patients treated with delamanid under compassionate use.

Hafkin J, Hittel N, Martin A, Gupta R.

Eur Respir J. 2017 Jul 27;50(1). pii: 1700311. doi: 10.1183/13993003.00311-2017. Print 2017 Jul. No abstract available.

5.

Delamanid in the treatment of multidrug-resistant tuberculosis.

Gupta R, Wells CD, Hittel N, Hafkin J, Geiter LJ.

Int J Tuberc Lung Dis. 2016 Dec 1;20(12):33-37. doi: 10.5588/ijtld.16.0125. Review.

PMID:
28240570
6.

Cost effectiveness of treating multi-drug resistant tuberculosis by adding Deltyba™ to background regimens in Germany.

Diel R, Hittel N, Schaberg T.

Respir Med. 2015 May;109(5):632-41. doi: 10.1016/j.rmed.2015.01.017. Epub 2015 Feb 4.

7.

Long-term mortality assessment of multidrug-resistant tuberculosis patients treated with delamanid.

Wells CD, Gupta R, Hittel N, Geiter LJ.

Eur Respir J. 2015 May;45(5):1498-501. doi: 10.1183/09031936.00176314. Epub 2015 Feb 19. No abstract available.

8.

Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients.

Diacon AH, Dawson R, Hanekom M, Narunsky K, Venter A, Hittel N, Geiter LJ, Wells CD, Paccaly AJ, Donald PR.

Int J Tuberc Lung Dis. 2011 Jul;15(7):949-54. doi: 10.5588/ijtld.10.0616.

PMID:
21682970
9.

A pooled analysis of the durability and predictors of treatment response of cilostazol in patients with intermittent claudication.

Pande RL, Hiatt WR, Zhang P, Hittel N, Creager MA.

Vasc Med. 2010 Jun;15(3):181-8. doi: 10.1177/1358863X10361545. Epub 2010 Apr 12.

10.

Down-regulation of interferon-gamma parallels clinical response to selective leukocyte apheresis in patients with inflammatory bowel disease: a 12-month follow-up study.

Muratov V, Lundahl J, Ulfgren AK, Elvin K, Fehrman I, Ahlborg N, Ost A, Hittel N, Saniabadi A, Löfberg R.

Int J Colorectal Dis. 2006 Sep;21(6):493-504. Epub 2006 Mar 15.

PMID:
16538495
11.
12.

Cilostazol treatment of claudication in diabetic patients.

Rendell M, Cariski AT, Hittel N, Zhang P.

Curr Med Res Opin. 2002;18(8):479-87.

PMID:
12564659
13.

Treating peripheral arterial disease in patients with diabetes.

Hittel N, Donnelly R.

Diabetes Obes Metab. 2002 Mar;4 Suppl 2:S26-31. Review.

PMID:
12180355
14.
15.

Direct analysis of resistance in the cutaneous microflora during treatment of acne vulgaris with topical 1% nadifloxacin and 2% erythromycin.

Bojar RA, Hittel N, Cunliffe WJ, Holland KT.

Drugs. 1995;49 Suppl 2:164-7. No abstract available.

PMID:
8549289
16.

Prolonged hypotensive effect of OPC-13340: a new, once-daily calcium channel blocking drug.

Broadhurst P, Brigden G, Hittel N, Lahiri A, Raftery EB.

Eur Heart J. 1991 Mar;12(3):434-8.

PMID:
2040326
17.

Short-term dietary sodium restriction increases serum lipids and insulin in salt-sensitive and salt-resistant normotensive adults.

Ruppert M, Diehl J, Kolloch R, Overlack A, Kraft K, Göbel B, Hittel N, Stumpe KO.

Klin Wochenschr. 1991;69 Suppl 25:51-7.

PMID:
1921253

Supplemental Content

Loading ...
Support Center